AESKU.GROUP finalizes acquisition of immunofluorescence assay specialist MBL Bion, expanding IFA product menu and production operations.
WENDELSHEIM, GERMANY, AND DES PLAINS, ILL. (PRWEB)AUGUST 01, 2019
AESKU.GROUP announced today it completed acquisition of immunofluorescence assay (IFA) specialist MBL BION from MBL Intl., securing their position as the leading provider of IFA solutions to clinical laboratories. The acquisition increases AESKU.GROUP’s addressable market and strengthens its market position.
AESKU.GROUP has a track record of developing, producing, and marketing innovative diagnostic assays and automated systems, and has a global network of proven distribution partners. A significant factor in their success is complete solutions for clinical laboratories, including all-in-one testing and reading automation with the SQII for enzyme immunoassay (ELISA), HELIA® for line immunoassay (LIA), and HELIOS®, which was the first all-in-one system on the market for IFA. This innovation, along with the confirmation of IFA as the gold-standard for autoimmunity screening in clinical guidelines, has led to over 400 HELIOS placements worldwide and increased demand for AESKU IFA reagents.
MBL Bion has over 40 years’ experience manufacturing IFA products of the highest quality and is a leading provider of autoimmunity and infectious disease testing slides. They have a strong market presence in the Americas, and a center of manufacturing excellence in Des Plains, IL, USA. Adding MBL Bion’s manufacturing capacity and broad range of reagents lets AESKU.GROUP help laboratories expand their IFA testing with the most extensive range of IFA products available on all-in-one automation combined with a unique quality control portfolio for the diagnosis of autoimmune and infectious diseases.
AESKU.GROUP CEO Dr. Torsten Matthias was delighted with the acquisition, saying, “We have found true synergy. MBL BION’s operations and product portfolio fit perfectly with the AESKU.GROUP. Between the expansion of our IFA manufacturing in Buffalo, NY, and MBL BION’s Des Plains operations, AESKU can speed order processing and delivery times. Furthermore, the high quality of their HEp-2 cells and extensive infectious disease testing slides add incredible value to our new HELIOS ‘HTC’ humidity and temperature control module. For the first time, clinical laboratories can access the highest level of automation and environmental control for both autoimmunity and infectious serology testing.”
About MBL BION
MBL BION, part of MBL Intl., a subsidiary of JSR Life Sciences, is an American company founded in 1978 that specializes in manufacturing high-quality IFA products for clinical laboratories. The company is FDA-registered and ISO 13485:2016 certified. They are experts in IFA for immunology, virology, and microbiology.
AESKU.GROUP, headquartered in Wendelsheim, Germany, includes AESKU.DIAGNOSTICS, AESKU.SYSTEMS, AESKU.THERAPY, and AESKU.KIPP INSTITUTE, and uses scientific expertise to translate basic research into accurate, reliable, and easy-to-use products. It employs more than 300 employees and has subsidiaries in the USA, China, England, Italy, Singapore, and Colombia. AESKU.GROUP provides autoimmunity, infectious disease, allergy, and food intolerance testing products to more than 90 countries around the world.
Founded in 2000, AESKU.GROUP is a recognized leader in autoimmunity testing and has recently expanded into allergy and infectious serology. Besides clinical assays and automation, it offers AESQC® quality standards, individual reagents, and software solutions for laboratory infrastructure (AESKU.LAB), with nearly 1000 installations worldwide.
The high quality of their HEp-2 cells and extensive infectious disease testing slides add incredible value to our new HELIOS ‘HTC’